Urogen Pharma Ltd. (URGN) — 8-K Filings

8-K Filings (22)

• 8-K Filing — May 6, 2026
• UroGen Pharma Ltd. Announces Executive and Board Changes — Aug 27, 2025 Risk: medium
  UroGen Pharma Ltd. announced on August 26, 2025, several key executive and board changes. The company elected new directors and appointed new officers, alongsid
• UroGen Pharma Ltd. Reports Board and Executive Changes — Jul 3, 2025 Risk: medium
  UroGen Pharma Ltd. announced on June 30, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the depa
• Deciphera to Acquire UroGen Pharma for $750M — Jun 13, 2025 Risk: medium
  UroGen Pharma Ltd. announced on June 12, 2025, that it has entered into a definitive agreement to be acquired by Deciphera Pharmaceuticals, LLC. The transaction
• UroGen Pharma Ltd. Files 8-K: Material Agreement & Equity Sales — Feb 20, 2025 Risk: medium
  UroGen Pharma Ltd. announced on February 14, 2025, that it entered into a material definitive agreement and also reported unregistered sales of equity securitie
• UroGen Pharma Files 8-K — Jan 14, 2025 Risk: low
  UroGen Pharma Ltd. filed an 8-K on January 14, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spe
• UroGen Pharma Files 8-K on Financials — Nov 6, 2024 Risk: low
  UroGen Pharma Ltd. filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statements an
• UroGen Pharma Appoints New CMO, Elects Directors — Oct 9, 2024 Risk: medium
  UroGen Pharma Ltd. announced on October 7, 2024, the appointment of Dr. Anup Rampersaud as Chief Medical Officer and the election of Ms. Sarah O'Connor and Mr.
• UroGen Pharma Ltd. Reports New Financial Obligation — Sep 24, 2024 Risk: medium
  UroGen Pharma Ltd. reported on September 23, 2024, that it has entered into a direct financial obligation. The filing does not specify the exact nature or amoun
• UroGen Pharma Appoints New CMO and Board Member — Sep 13, 2024 Risk: medium
  UroGen Pharma Ltd. announced on September 12, 2024, changes in its executive team and board of directors. Specifically, Dr. Elizabeth O'Farrell has been appoint
• UroGen Pharma to be Acquired by Foundry Acquisition — Aug 15, 2024 Risk: medium
  UroGen Pharma Ltd. announced on August 14, 2024, that it has entered into a definitive agreement to be acquired by Foundry Acquisition, Inc. The transaction is
• UroGen Pharma Files 8-K on Operations — Aug 13, 2024 Risk: low
  UroGen Pharma Ltd. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and
• UroGen Pharma Appoints New CMO, CCO, and Board Member — Aug 8, 2024 Risk: medium
  UroGen Pharma Ltd. announced on August 6, 2024, several key executive and board changes. Dr. Arun Singh has been appointed as Chief Medical Officer, and Ms. Jen
• UroGen Pharma Raises $100M in Public Offering — Jun 18, 2024 Risk: medium
  UroGen Pharma Ltd. announced on June 17, 2024, the closing of its previously announced underwritten public offering of 10,350,000 ordinary shares, raising appro
• Deciphera to Acquire UroGen Pharma for $755M — Jun 13, 2024 Risk: medium
  UroGen Pharma Ltd. announced on June 13, 2024, that it has entered into a definitive agreement to be acquired by Deciphera Pharmaceuticals, LLC. The transaction
• UroGen Pharma Files 8-K for Operations and Financials — May 13, 2024 Risk: low
  UroGen Pharma Ltd. filed an 8-K on May 13, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exh
• UroGen Pharma Files 8-K for Financial Updates — Mar 14, 2024 Risk: low
  UroGen Pharma Ltd. filed an 8-K on March 14, 2024, to report on its results of operations and financial condition, as well as to file financial statements and e
• UroGen Pharma Files 8-K — Mar 4, 2024 Risk: low
  UroGen Pharma Ltd. filed an 8-K on March 4, 2024, to report on Regulation FD disclosures and financial statements. The filing does not contain specific financia
• AbbVie to Acquire UroGen Pharma for $750M — Mar 1, 2024 Risk: medium
  UroGen Pharma Ltd. announced on March 1, 2024, that it has entered into a definitive agreement to be acquired by Allergan Aesthetics, an AbbVie company. The tra
• UroGen Pharma Files 8-K for Reg FD Disclosure, Exhibits — Feb 7, 2024
  UroGen Pharma Ltd. filed an 8-K on February 7, 2024, primarily to disclose information under Regulation FD and to include financial statements and exhibits. Thi
• UroGen Pharma Enters Material Definitive Agreement — Jan 17, 2024
  UroGen Pharma Ltd. filed an 8-K on January 17, 2024, reporting an "Entry into a Material Definitive Agreement" and "Other Events" that occurred on January 16, 2
• UroGen Pharma Enters Material Definitive Agreement on Dec 28 — Jan 2, 2024
  UroGen Pharma Ltd. filed an 8-K on January 2, 2024, to report a material definitive agreement entered into on December 28, 2023. This filing indicates a signifi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX